SGCB and renal fibrosis: Previous studies have shown that chronic treatment with sGC stimulators such as BAY 41-2272 or BAY 63-2521) at doses of 10 mg/kg/day inhibited a range of pro-fibrotic markers in renal fibrosis [53], [54], as well as hypertension-induced cardiac fibrosis [20], [55]; these antifibrotic effects were all secondary to reductions in blood pressure.